8/12/99 - 3:30 PM

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 10-Q
             QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

(X)     Quarterly report for the quarterly period ended         June 30, 1999

                                       OR

(   )      Transition Report Pursuant to Section 13 or 15(d) of The Securities
           Exchange Act of 1934

Commission file number                                   1-9601

                           K-V PHARMACEUTICAL COMPANY

             (Exact name of registrant as specified in its charter)

           DELAWARE                                     43-0618919
(State or other jurisdiction of            (I.R.S. Employer Identification No.)
incorporation or organization)

                2503 SOUTH HANLEY ROAD, ST. LOUIS, MISSOURI 63144

                    (Address or principal executive offices)
                                   (Zip Code)

                                 (314) 645-6600

              (Registrant's telephone number, including area code)



              (Former name, former address and former fiscal year,
                         if changed since last report)

         Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934 during the preceding 12 months (or such shorter  period that the registrant
was  required  to file such  reports)  and (2) has been  subject to such  filing
requirements for the past 90 days.

Yes  X     No

   Title of Class of                             Number of Shares
     Common Stock                        Outstanding as of this Report Date
   -----------------                     ----------------------------------

Class A Common Stock, par value $.01 per share              11,906,157
Class B Common Stock, par value $.01 per share               6,489,561


                                       1


<PAGE>





                                     PART I

                              FINANCIAL INFORMATION












                                        2



<PAGE>


                   KV PHARMACEUTICAL COMPANY AND SUBSIDIARIES
                        CONSOLIDATED STATEMENTS OF INCOME
                For the Three Months Ended June 30, 1999 and 1998
                    (Dollars in 000's except per share data)
                                   (Unaudited)
<TABLE>
<CAPTION>


                                                         1999                          1998
                                                        ------                        ------
<S>                                                 <C>                          <C>

Net Revenues                                            $32,794                       $25,670

Costs and Expenses:
   Manufacturing costs and expenses                      16,532                        15,155
   Research and development                               1,828                         1,643
   Selling and administrative                             8,046                         4,857
   Amortization of intangible assets                        500                            42
                                                        -------                       -------
Total costs and expenses                                 26,906                        21,697
                                                        -------                       -------

Operating income                                          5,888                         3,973
                                                        -------                       -------

Other income (expense):
   Interest expense                                        (581)                         (114)
   Interest and other income                                145                           291
                                                        -------                       -------
Total other income (expense)                               (436)                          177
                                                        -------                       -------


Income before income taxes                                5,452                         4,150
Provision for income taxes                                2,073                         1,580
                                                        -------                       -------

Net Income                                              $ 3,379                       $ 2,570
                                                        =======                       =======

Net Income per Common Share-Basic (after
    deducting preferred dividends
    of $105 in 1999 and 1998):                            $0.18                         $0.14
                                                          =====                         =====

Net Income per Common Share-Diluted                       $0.17                         $0.13
                                                          =====                         =====

</TABLE>


See Accompanying Notes to Consolidated Financial Statements


                                       3



<PAGE>


                   KV PHARMACEUTICAL COMPANY AND SUBSIDIARIES
                           CONSOLIDATED BALANCE SHEETS
             June 30, 1999 (Unaudited) and March 31, 1999 (Audited)
                               (Dollars in 000's)

<TABLE>
<CAPTION>

                                                                                06/30/99            03/31/99
                                                                                --------            --------
<S>                                                                          <C>              <C>

ASSETS
------
Current Assets:
  Cash and cash equivalents                                                     $  5,613          $  2,617
  Marketable securities, available-for-sale                                        4,966             7,523
  Receivables, less allowance for doubtful accounts of
    $1,017 and $631 at June 30, 1999 and March 31, 1999, respectively             21,488            18,988
  Receivable, arbitration award                                                        -            13,253
  Inventories                                                                     23,448            23,653
  Deferred income taxes                                                            3,404             3,379
  Prepaid and other current assets                                                   107               168
                                                                                --------          --------
     Total Current Assets                                                         59,026            69,581

Property and equipment, less accumulated depreciation                             20,702            18,967

Intangibles and other assets, net of amortization                                 39,354            39,442
                                                                                --------          --------
TOTAL ASSETS                                                                    $119,082          $127,990
                                                                                ========          ========
LIABILITIES
-----------
Current Liabilities:
  Accounts payable                                                              $  7,035          $  8,667
  Accrued liabilities                                                             10,964            17,090
  Current maturities of long-term debt                                               712               712
                                                                                --------          --------
     Total Current Liabilities                                                    18,711            26,469
Long-term debt                                                                    26,394            31,490
Deferred income taxes                                                                379               379
Other long-term liabilities                                                        2,168             2,104
                                                                                --------          --------

  TOTAL  LIABILITIES                                                              47,652            60,442
                                                                                --------          --------

SHAREHOLDERS' EQUITY
--------------------
7% Cumulative  Convertible  Preferred Stock,  $.01 par value;  $25.00 stated
and liquidation value; 840,000 shares authorized; issued and outstanding -
240,000 and 241,000 shares at June 30, 1999 and March 31, 1999, respectively           2                 2
(convertible into Class A shares at a ratio of 3.75 to one)

Class A and Class B Common Stock, $.01 par value;
 150,000,000 and 75,000,000 shares authorized, respectively;
 Class A-issued 11,941,776 and 11,923,319 as of June 30, 1999 and March 31,
 1999, respectively                                                                  120               120
 Class B-issued 6,525,180 and 6,393,867 as of June 30, 1999 and March 31, 1999,
 respectively (convertible into Class A shares on a one-for-one basis)                65                64
Additional paid-in capital                                                        35,153            34,531
Retained earnings                                                                 36,185            32,911
Accumulated comprehensive loss, net                                                  (40)              (25)
Less: Treasury stock, 35,619 shares each of
  Class A and Class B Common Stock, at cost                                          (55)              (55)
                                                                                --------         ---------
  TOTAL SHAREHOLDERS' EQUITY                                                      71,430            67,548
                                                                                --------         ---------
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY                                      $119,082          $127,990
                                                                                ========          ========

</TABLE>

See Accompanying Notes to Consolidated Financial Statements

                                       4


<PAGE>


                   KV PHARMACEUTICAL COMPANY AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                For the Three Months Ended June 30, 1999 and 1998
                               (Dollars in 000's)
                                   (Unaudited)

<TABLE>
<CAPTION>

                                                                   1999             1998
                                                                   ----             ----
<S>                                                            <C>             <C>
OPERATING ACTIVITIES
Net Income                                                        $ 3,379          $ 2,570
Adjustments to reconcile net income to net
   cash provided by operating activities:
   Depreciation and amortization                                      954              434
   Changes in deferred taxes                                          (24)               -
   Changes in deferred compensation                                    64              130
Changes in operating assets and liabilities:
   (Increase) decrease in receivables                              (2,500)           3,318
   Decrease in receivable arbitration award                        13,253                -
   Decrease (increase) in inventories                                 204             (350)
   (Increase) decrease in prepaid and other assets                   (351)               4
   Decrease in accounts payable and accrued liabilities            (7,758)          (1,721)
                                                                  -------          -------
NET CASH PROVIDED BY OPERATING ACTIVITIES                           7,221            4,385
                                                                  -------          -------

INVESTING ACTIVITIES
   Purchase of property and equipment, net                         (2,189)            (544)
   Sale of marketable securities                                    2,543                -
                                                                  -------          -------

NET CASH PROVIDED  BY (USED IN)
INVESTING ACTIVITIES                                                  354             (544)
                                                                  -------          -------

FINANCING ACTIVITIES
   Principal payments on long-term debt                            (5,097)             (59)
   Dividends paid on Preferred Stock                                 (105)            (105)
   Exercise of Common Stock options                                   623              283
                                                                  -------          -------
NET CASH (USED IN) PROVIDED BY
FINANCING ACTIVITIES                                               (4,579)             119
                                                                  -------          -------

INCREASE IN CASH AND CASH EQUIVALENTS                               2,996            3,960
CASH AND CASH EQUIVALENTS AT:
   BEGINNING OF YEAR                                                2,617           18,158
                                                                  -------          -------
   END OF PERIOD                                                  $ 5,613          $22,118
                                                                  =======          =======

</TABLE>


See Accompanying Notes to Consolidated Financial Statements

                                       5




<PAGE>

              NOTES TO SUMMARIZED CONSOLIDATED FINANCIAL STATEMENTS



NOTE A -- BASIS OF PRESENTATION

                  The  interim  financial  statements  presented  here have been
prepared in conformity with the accounting  principles and practices and methods
of applying the same (including consolidating practices) reflected in the Annual
Report of the  Company on Form 10-K for the year ended March 31, 1999 filed with
the  Securities  & Exchange  Commission,  except  that  detailed  footnotes  and
schedules  are not  included.  Reference  is hereby  made to the  footnotes  and
schedules contained in the Annual Report. All significant  intercompany balances
and  transactions  have been eliminated  and, in the opinion of management,  all
adjustments, which are of a normal recurring nature only, necessary to present a
fair  statement  of the results of the Company  and its  subsidiaries  have been
made.


                                       6


<PAGE>


NOTE B  -  EARNINGS PER SHARE

         The  following  table is  presented  in  thousands  and sets  forth the
computation of basic and diluted earnings per share:

<TABLE>
<CAPTION>

                                                 For the Three Months Ended June 30,
Numerator:                                              1999            1998
                                                        ----            ----
<S>                                                 <C>           <C>

Net income                                             $ 3,379       $ 2,570

Preferred Stock dividends                                 (105)         (105)
                                                       -------       -------
Numerator for basic earnings per
   share--income available to common
   shareholders                                          3,274         2,465

Effect of dilutive securities:
   Preferred Stock dividends                               105           105
                                                       -------       -------

Numerator for diluted earnings per
   share-income available to
   common shareholders after
   assumed conversions                                 $ 3,379      $ 2,570
                                                       =======      =======

Denominator:

Denominator for basic earnings per
   share--weighted-average shares                       18,373       18,145
                                                       -------       ------

Effect of dilutive securities:
   Employee stock options                                  609          940
   Convertible Preferred Stock                             900          904
                                                       -------       ------

Dilutive potential Common Shares                         1,509        1,844
                                                       -------       ------

Denominator for diluted earnings
   per share--adjusted weighted-average
   shares and assumed conversions                       19,882       19,989
                                                       =======      =======

Basic Earnings per Share (1):                           $ 0.18       $ 0.14
                                                        ======       ======

Diluted Earnings per Share (1) (2) (3):                 $ 0.17       $ 0.13
                                                        ======       ======

</TABLE>

(1) The  two-class  method for Class A and Class B Common Stock is not presented
    because the earnings  per share are  equivalent  to the if converted  method
    since dividends were not declared or paid and each class of common stock has
    equal ownership of the Company.

(2) Employee  stock  options to purchase  61,750 shares at June 30, 1999 and 750
    shares at June 30,  1998 are not  included  in the  computation  of  diluted
    earnings per share because they are  anti-dilutive.  The exercise  prices of
    these options  exceeded the average market prices of the shares under option
    in each respective period.

(3) The  options to purchase  Class A Common  Stock sold in  connection  with an
    agreement  entered into in January 1996 are not included in the  computation
    of diluted EPS because the options'  minimum exercise price was greater than
    the average  market  price of the Class A Common  Shares.  All options  sold
    under this agreement expired September 29, 1998.


                                       7

<PAGE>

NOTE C - SEGMENT  FINANCIAL  INFORMATION

          The reportable  segments of the Company are specialty generics
and  pharmaceutical  services.  Segment  operating results are measured based on
income before taxes.

<TABLE>
<CAPTION>


                                                                                                   Corporate
                                             Specialty        Pharmaceutical         All         Expenses and
June 30, 1999  ($ in 000's)                   Generics           Services           Other        Eliminations       Consolidated
--------------------------------              --------           --------           -----        ------------       ------------
<S>                                        <C>               <C>                <C>            <C>                <C>

Revenues                                       $25,389           $10,809             $ 6,769       $(10,173)           $32,794
Depreciation and amortization                       31               378                  45            500                954
Income before income taxes                      10,644              (169)                942         (5,965)             5,452
Total assets                                   138,615            42,448               8,504        (70,485)           119,082
Capital expenditures                                 -             2,189                   -              -              2,189



June 30, 1998  ($ in 000's)
Revenues                                       $20,653          $  6,485             $ 3,776        $(5,244)           $25,670
Depreciation and amortization                       18               352                  22             42                434
Income before income taxes                       7,925              (105)                683         (4,353)             4,150
Total assets                                   101,412            42,727              15,769        (90,450)            69,458
Capital expenditures                                 9               535                   -              -                544



</TABLE>



NOTE D - SUBSEQUENT EVENT: PRODUCT  ACQUISITION

         On August 2,  1999,  the  Company  acquired  the  worldwide  rights and
trademark for the prescription prenatal product, PreCare(R), from UCB Pharma for
$8.5 million.  The purchase  price was funded by $4 million in cash payments and
$4 million in Class A Common  Stock,  which is guaranteed to have a market value
of not less than $4.5 million on August 2, 2000 and can be repurchased by KV for
the same amount.

          The  PreCare(R)  product had net sales of $4.3 million in 1998
and  competes  in  a  total  U.S.  market  of  approximately  $100  million  for
prescription  prenatal  supplementation  products.  The Company plans to use the
PreCare(R) trade name as a brand franchise for other uniquely positioned, patent
protected  women's  healthcare  products planned for introduction in fiscal 2000
and 2001.  Profits from the addition of the  PreCare(R)  product are expected to
have an accretive earnings effect during the current fiscal year.

NOTE E - LONG-TERM DEBT

         On June 22, 1999, the Company  amended its "Revolving  Note"  Agreement
with LaSalle  National Bank to extend the "Revolving  Credit Maturity Date" from
June 15,  2000 to  October  15,  2000.  All other  terms and  conditions  of the
agreement remained the same.

                                       8


<PAGE>


         Any forward-looking statements set forth in this Report are necessarily
subject to significant  uncertainties and risks.  When used in this Report,  the
words "believes,"  "anticipates,"  "intends," "expects," and similar expressions
are intended to identify  forward-looking  statements.  Actual  results could be
materially different as a result of various possibilities. Readers are cautioned
not to place undue reliance on forward-looking  statements,  which speak only as
of the date hereof. The Company undertakes no obligation to publicly release any
revisions to these forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events.

Item 2.   Management's  Discussion and Analysis of Results of Operations,
          and Liquidity and Capital Resources

     (a)  Results of Operations

         Revenues.  Consolidated  net revenues  for the first  quarter of fiscal
2000 ended June 30, 1999 increased $7.1 million, or 27.8%, to $32.8 million from
$25.7  million for the same period last year.  The  increase in revenues was due
primarily to higher sales of specialty  generics and brand  products.

         Specialty   generic  sales  through  the  Company's  ETHEX   subsidiary
increased $4.7 million, or 22.9%, during the quarter to $25.4 million due to net
volume increases across the majority of the product line ($3.7 million), and net
price increases ($1.0 million). The volume increase includes increases in market
share in cardiovascular  and women's health categories ($5.2 million) and a full
quarter's impact of products introduced in the prior year ($2.1 million).

         Brand product sales through the Company's Ther-Rx subsidiary  represent
sales for the quarter of the  Micro-K(R)  product line ($2.7  million)  acquired
from  American  Home  Products in March 1999.  The Company  began  promoting the
product  through its detail sales force late in the first  quarter and expects a
positive  effect on revenues  over the next  several  quarters  as  prescription
volume  increases  in  response  to this  selling  effort.


                                       9


<PAGE>


         Costs and Expenses.  Manufacturing  costs  increased  $1.4 million,  or
9.1%, during the quarter to $16.5 million due to increased volume. Manufacturing
costs as a percent  of  revenues  declined  to 50.4% from 59.0% last year due to
favorable product mix and improved margins and pricing as shown in the following
table:

                                                  %  Revenues
                                                  -----------

     FY99 Manufacturing Costs                         59.0%
     Change due to:
       Product mix                                    (5.1)
       Pricing                                        (3.5)
     FY00 Manufacturing Costs                         50.4%

         Research and development costs increased $.2 million, or 11.2%, to $1.8
million during the quarter from $1.6 million in last year's first  quarter.  The
increase was primarily due to higher personnel and related  supplies  ($126,000)
and higher levels of clinical testing ($42,000) to support increased activity in
the  research and  development  of products.  The Company  expects  research and
development  expenses  to continue  to  increase  over the next two  quarters to
support planned new product  development.

         Selling and administrative  expenses increased $3.2 million,  or 65.7%,
to $8.0  million  during the  quarter  from $4.8  million in last  year's  first
quarter. As a percent of revenues, selling and administrative expenses increased
to 24.5% from 18.9% last year.  The increase was due primarily to added expenses
in the  sales,  marketing  and  administrative  areas of the  Company to support
branded sales and marketing ($1.8 million),  increased advertising and promotion
($.8 million) and  additional  personnel  ($.5 million).

         Amortization  expense increased $.5 million related to the amortization
of acquired product rights.

         Interest  expense  increased $.5 million during the quarter compared to
the  same  period  last  year  due to  increased  debt  incurred  for a  product
acquisition.

         Net Income.  As a result of the  factors  described  above,  net income
improved $.8 million,  or 31.5%,  to $3.4 million in the first quarter of fiscal
2000 from net income of $2.6 million in the first quarter of fiscal 1999.


                                       10

<PAGE>



     (b) Liquidity and Capital Resources

         Cashflow.  Cashflow  from  operations  was $7.2  million  for the first
quarter of fiscal 2000,  an increase of $2.8 million,  or 64.7%,  over the first
quarter of last year.  The increase in operating cash flow compared to last year
was due to  higher  net  income  before  depreciation,  amortization  and  other
non-cash charges ($1.2 million),  the collection of an arbitration  award ($13.3
million) and a decrease in inventory ($.5 million). The increases were partially
offset by an increase in trade accounts receivable ($5.8 million), a decrease in
accounts  payable  ($3  million)  and a  decrease  in  accrued  liabilities  ($3
million).  The increase in trade  accounts  receivable  reflects the increase in
sales and timing of customer  orders for the  quarter.  The decrease in accounts
payable was due to a reduction in the  purchase of raw  material  and  packaging
inventories  due to improved  material  requirements  planning.  The decrease in
accrued liabilities was due primarily to a decrease in accrued income taxes paid
in the quarter related to the arbitration award recorded in fiscal 1999.

         Investing   activities   for  the  first   quarter   included   capital
expenditures  of $2.2 million,  offset by the sale of $2.5 million of marketable
securities.  Capital  expenditures  were  primarily  for  production  equipment,
laboratory  improvements and the upgrade of the Company's  business software and
network  systems.  Marketable  securities  were sold in  anticipation of further
reductions  in long term  debt in the  second  quarter.

         The Company paid down  long-term  debt  associated  with a product line
acquisition  by $5.1  million  using  cash  provided  by  operations  during the
quarter.

         The Company believes that existing cash and securities  balances,  cash
generated  from  operating  activities  and funds  available  under  its  credit
facility  will  be  adequate  to fund  operating  activities  for the  presently
foreseeable  future  including  the  payment  of short  term and long  term debt
obligations, capital improvements,  product development activities and expansion
of marketing capabilities for the branded pharmaceutical business.


                                       11

<PAGE>

         Balance  Sheet and  Ratios.  The  following  table sets forth  selected
balance sheet data and financial  ratios at June 30 and year-end March 31, 1999:

                                                  ($ in 000's)
                                             6/30/99        3/31/99
                                             -------        --------
          Working Capital                    40,315         43,112
          Working Capital Ratio              3.2 to 1       2.6 to 1
          Quick Assets                       32,067         42,381
          Quick Ratio                        1.7 to 1       1.1 to 1
          Long-Term Debt                     26,394         31,491
          Stockholders' Equity               71,431         67,548
          Long-Term Debt to Equity           .37 to 1       .47 to 1


         Working  capital  decreased  $2.8  million  during  the first  quarter,
compared to the balance at the end of fiscal 1999, as current  assets  decreased
$10.6 million, or 15.2 %, while current  liabilities  decreased $7.8 million, or
29.3%. The decrease in current assets was due primarily to the collection of the
$13.3 million arbitration  receivable at year-end,  the proceeds from which were
used to pay  income  taxes  ($6.0  million),  fund  capital  expenditures  ($2.2
million)  and pay  down  long-term  debt  ($5.1  million).  Current  liabilities
decreased primarily due to a $5.1 million decrease in accrued income taxes and a
$1.6 million reduction in accounts payable from lower inventory purchases. Quick
assets declined $10.3 million,  or 24%, due primarily to the utilization of cash
for the aforementioned expenditures on taxes, capital expenditures and reduction
of long-term  debt. The working capital ratio improved to 3.2 to 1 and the quick
ratio to 1.7 to 1 as current liabilities  declined at a faster rate than current
assets and quick assets.

         The debt to equity  ratio  improved  during the  quarter due to the pay
down of long-term debt and the increase in stockholders'  equity attributable to
the Company's net income for the quarter.

         Inflation.  Although  at  reduced  levels  in recent  years,  inflation
continues to apply upward pressure on the cost of goods and services used by the
Company.  However,  the Company believes that the net effect of inflation on its
operations  has been minimal  during the current  quarter and the prior year. In
addition,  changes in the mix of products sold and the effect of competition has
made a  comparison  of changes in selling  prices  less  meaningful  relative to
changes in the overall rate of inflation during the quarter and prior year.

                                       12

<PAGE>

         Year  2000  Project.   The  Company  utilizes   computer   technologies
throughout  its business to  effectively  carry out its  day-to-day  operations.
Computer  technologies  include  both  information  technology  in the  form  of
hardware  and  software,  as  well  as  embedded  technology  in  the  Company's
facilities and equipment.  Similar to most companies, the Company must determine
whether its systems are capable of  recognizing  and  processing  date-sensitive
information  properly as the year 2000  approaches.  The Company is  utilizing a
multi-phased  concurrent  approach to address this issue. The phases included in
the Company's approach are the awareness,  assessment,  validation,  remediation
and implementation  phases. The Company has completed the awareness,  assessment
and validation  phases and is very active in the remediation and  implementation
phases.

         The  Company  currently  intends  to  complete  the year 2000  project,
including the few testing and remediation tasks that remain,  prior to September
30,  1999.  The costs  associated  with the project  are not  expected to exceed
$766,000  (of which  approximately  $587,000  had been  incurred  as of June 30,
1999),  and are not  deemed to  materially  impact  the  Company's  consolidated
financial position,  results of operations or cash flows in future periods.  The
Company is actively correcting and replacing the remaining systems which are not
year 2000 ready in order to ensure the Company's ability to continue to meet its
internal  needs  and  those of its  customers  and  suppliers.

         The  Company  is  finalizing  formal  communications  with  all  of its
significant  suppliers  and critical  business  partners to determine  year 2000
compliance of its  dependents  and has developed  contingency  plans to minimize
interruptions  in business  in the event a third party is unable to perform.  An
interruption of the Company's ability to conduct its business due to a year 2000
readiness  problem  could have a material  adverse  effect on the  Company.  The
Company is not presently aware of any such significant exposure;  however, there
can be no  guarantee  that the  systems of third  parties  on which the  Company
relies  will be  converted  in a timely  manner  or that a failure  to  properly
convert  by another  company  would not have a  material  adverse  effect on the
Company.

                                       13


<PAGE>

         The  Company  presently   believes  that  the  most  reasonably  likely
worst-case  scenarios  that the Company might confront with respect to Year 2000
issues have to do with third parties not being Year 2000 compliant.  The Company
is finalizing the evaluation of vendor compliance and has developed  contingency
plans,  such as  alternate  vendor  opportunities,  in the event a vendor is not
available.

         Based upon the  planning  and  implementation  completed  to date,  the
Company believes that, with modifications to existing  software,  conversions to
new software and appropriate  remediation of embedded chip  equipment,  the Year
2000 issue is not reasonably likely to pose significant operational problems for
the Company's  information  technology systems and embedded chip equipment as so
modified and converted.


                                       14

<PAGE>




                           PART II. OTHER INFORMATION

Item 6:   Exhibits and Reports on Form 8-K.

          (a)  No Exhibits

          (b)  Reports  on Form 8-K.  A report  on Form 8-K dated  April 5,
               1999 reporting KV Pharmaceutical  Company's  acquisition of the
               world-wide rights and trademark to  Micro-K(R)  from Wyeth
               Ayerst  Laboratories,  the  pharmaceutical division of American
               Home Products Corporation and a report on Form 8-K/A dated
               June 2, 1999 amending Form 8-K filed on April 5,1999.


                                       15


<PAGE>


                                   SIGNATURES

         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  Registrant  has duly  caused  this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                        KV PHARMACEUTICAL COMPANY




Date:     August 13, 1999                  /s/ Marc S. Hermelin
                                        -------------------------------------
                                        Marc S. Hermelin
                                        Vice Chairman of the Board and
                                        Chief Executive Officer





Date:     August 13, 1999                  /s/ Gerald R. Mitchell
                                        -------------------------------------
                                        Gerald R. Mitchell
                                        Vice President - Finance
                                        Chief Financial Officer


                                       16